Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Allstate Corp (ALL) vs Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Price & Performance

Allstate CorpTrade
Bio-Rad Laboratories, Inc. Class A Common StockTrade

Price performance (Past 24H)

Key statistics

Allstate Corp vs Bio-Rad Laboratories, Inc. Class A Common Stock — how do they compare? Allstate Corp trades at $262.1 (market cap $68.19B), while Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B). The key difference: Allstate Corp is far larger — about 7.3× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Allstate Corp pays a 1.6% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.

ALLBIO
Market Cap
$68.19B$9.39B
Sector
FinancialsHealth
52-Week High
$275.11$354.54
52-Week Low
$190.00$241.71
Enterprise Value
$76.84B$9.14B
Dividend Yield
1.6%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Allstate Corp

Allstate (ALL) trades at $267.00, down 2.95% on the day, but maintains a bullish technical signal with strong fundamental momentum. The company reported robust Q2 2026 earnings of $8.99 per share, beating estimates, and has consistently exceeded expectations in recent quarters. Revenue growth is steady, with 2025 revenue at $67.07 billion and net income margin improving to 19.19%. The stock is attractively valued with a P/E of 5.35 and offers a dividend, with recent payouts of $1.08 per share.

The outlook for ALL is positive, driven by strong underwriting performance and earnings beats, though sustainability of peak profitability is a concern. Investment opportunity lies in its low valuation and dividend yield, but risks include potential normalization of underwriting results and competitive pressures. Analyst consensus is mixed with a $266.54 price target, indicating limited near-term upside from current levels.

Bio-Rad Laboratories, Inc. Class A Common Stock

BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.

The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Allstate Corp

On the basis of premium sales, Allstate is one of the largest U.S. property and casualty insurers. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 10,000 agencies.

Read more on ALL

About Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

Read more on BIO